CERE
T. Rowe Price Associates’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-53,401
| Closed | -$2.18M | – | 3047 |
|
|
2024
Q2 | $2.18M | Sell |
53,401
-281,956
| -84% | -$11.5M | ﹤0.01% | 1516 |
|
|
2024
Q1 | $14.2M | Sell |
335,357
-385,698
| -53% | -$16.3M | ﹤0.01% | 1052 |
|
|
2023
Q4 | $30.6M | Sell |
721,055
-4,782,443
| -87% | -$203M | ﹤0.01% | 842 |
|
|
2023
Q3 | $120M | Buy |
5,503,498
+278,698
| +5% | +$6.08M | 0.02% | 479 |
|
|
2023
Q2 | $166M | Buy |
5,224,800
+425,093
| +9% | +$13.5M | 0.02% | 425 |
|
|
2023
Q1 | $117M | Sell |
4,799,707
-4,887
| -0.1% | -$119K | 0.02% | 481 |
|
|
2022
Q4 | $152M | Buy |
4,804,594
+35,520
| +0.7% | +$1.12M | 0.02% | 426 |
|
|
2022
Q3 | $135M | Sell |
4,769,074
-1,526,834
| -24% | -$43.1M | 0.02% | 433 |
|
|
2022
Q2 | $166M | Sell |
6,295,908
-182,102
| -3% | -$4.81M | 0.02% | 523 |
|
|
2022
Q1 | $227M | Buy |
6,478,010
+477,088
| +8% | +$16.7M | 0.02% | 491 |
|
|
2021
Q4 | $195M | Buy |
6,000,922
+160,191
| +3% | +$5.19M | 0.02% | 562 |
|
|
2021
Q3 | $172M | Buy |
5,840,731
+2,513,320
| +76% | +$74.1M | 0.02% | 593 |
|
|
2021
Q2 | $85.2M | Sell |
3,327,411
-72,477
| -2% | -$1.86M | 0.01% | 844 |
|
|
2021
Q1 | $46.7M | Buy |
3,399,888
+7,755
| +0.2% | +$106K | ﹤0.01% | 1026 |
|
|
2020
Q4 | $54M | Buy |
+3,392,133
| New | +$54M | 0.01% | 934 |
|